Ratings Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:31 2024-05-31 am EDT			5-day change	1st Jan Change
1,937 ^DKK	+0.31%		+0.55%	-10.12%

May. 21	Genmab A/S Reaffirms Financial Guidance for 2024	CI
May. 21	Genmab A/S completed the acquisition of ProfoundBio, Inc.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company benefits from high valuations in earnings multiples.
With an enterprise value anticipated at 5 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
GENMAB A/S	-10.12%	18.16B	A-
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B	B+
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B	B+
BIONTECH SE	-4.68%	24.28B	B+
ARGENX SE	-0.82%	21.96B	B
WUXI APPTEC CO., LTD.	-42.12%	16.37B	A-
BEIGENE, LTD.	-17.47%	15.56B	B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B	C+
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B	C+
INSMED INCORPORATED	+77.64%	8.87B	C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes